SCHEMBL9924679

SCHEMBL9924679

NCCNC(=O)C1CC2C=CC1C2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.59
LMNA P02545 1/20 0.59
EPHX2 P34913 3/20 0.43
ESR1 P03372 1/20 0.42
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 4/20 0.40
KMT2A Q03164 2/20 0.40
THRB P10828 1/20 0.40
MC4R P32245 1/20 0.40
POLB P06746 3/20 0.36
APEX1 P27695 1/20 0.36
RECQL P46063 1/20 0.36
BLM P54132 1/20 0.36
ESR2 Q92731 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25361465 0.88 KDM4E (0.53) KDM4ELMNAEPHX2ESR1RAB9A
SCHEMBL15076059 0.88 KDM4E (0.53) KDM4ELMNAEPHX2ESR1RAB9A
SCHEMBL16883512 0.85 KDM4E (0.50) KDM4ELMNAEPHX2ESR1RAB9A
SCHEMBL11064771 0.85 KDM4E (0.61) KDM4ELMNAEPHX2ESR1RAB9A
SCHEMBL11064769 0.85 KDM4E (0.61) KDM4ELMNAEPHX2ESR1RAB9A
SCHEMBL27353983 0.84 KDM4E (0.49) KDM4ELMNAEPHX2ESR1RAB9A
SCHEMBL10124090 0.83 KDM4E (0.59) KDM4ELMNAEPHX2ESR1RAB9A
SCHEMBL14392991 0.83 KDM4E (0.59) KDM4ELMNAEPHX2ESR1RAB9A
SCHEMBL14611026 0.81 KDM4E (0.46) KDM4ELMNAEPHX2ESR1RAB9A
SCHEMBL6137154 0.81 KDM4E (0.65) KDM4ELMNAEPHX2ESR1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216573-A1 COMPOSITIONS COMPRISING CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF HALLURA LTD. (IL) 2024-07-04 US disclosed
US-9040626-B2 Nanofibers and morphology shifting micelles THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-05-26 US disclosed
US-9040626-B2 Nanofibers and morphology shifting micelles THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-05-26 US disclosed
US-20120149843-A1 NANOFIBERS AND MORPHOLOGY SHIFTING MICELLES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-06-14 US disclosed
US-20120149843-A1 NANOFIBERS AND MORPHOLOGY SHIFTING MICELLES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149843-A1 NANOFIBERS AND MORPHOLOGY SHIFTING MICELLES MFAP1, LGALS4, TLN1 KDM4E 2687/4885LMNA 62/4885EPHX2 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.